NEW YORK (GenomeWeb News) – Accelerate Diagnostics today said that its revenues in the second quarter dropped three-fold year over year.

Revenues for the three months ended June 30 were $7,373, down from $22,721 a year ago, Accelerate said in its Form 10-Q filed with the US Securities and Exchange Commission. All revenues for the recently completed quarter and the year-ago period derived from royalty payments for its OptiChem products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.